Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The 2012 trivalent influenza vaccine is a seasonal, inactivated viral vaccine designed to provide protection against three strains of the influenza virus. For the 2012 Southern Hemisphere season, the formulation typically included an A/California/7/2009 (H1N1)pdm09-like virus, an A/Perth/16/2009 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus. This specific study conducted by the University of Sao Paulo evaluated the immunogenicity and safety of the vaccine when administered intradermally using a needle-free disposable-syringe jet injector (DSJI) compared to traditional intramuscular injection. The goal of such studies is often dose-sparing, where a smaller volume of vaccine delivered into the dermis (which is rich in antigen-presenting cells) can elicit an immune response comparable to a full dose delivered intramuscularly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2012 trivalent influenza vaccine (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo).